Human pilot studies reveal the potential of a vitronectin: growth factor complex as a treatment for chronic wounds.

ABSTRACT: Several different advanced treatments have been used to improve healing in chronic wounds, but none have shown sustained success. The application of topical growth factors (GFs) has displayed some potential, but the varying results, high doses and high costs have limited their widespread adoption. Many treatments have ignored the evidence that wound healing is driven by interactions between extracellular matrix proteins and GFs, not just GFs alone. We report herein that a clinical Good Manufacturing Practice-grade vitronectin:growth factor (cVN:GF) complex is able to stimulate functions relevant to wound repair in vitro, such as enhanced cellular proliferation and migration. Furthermore, we assessed this complex as a topical wound healing agent in a single-arm pilot study using venous leg

SUBMITTER: Upton Z 

PROVIDER: S-EPMC7950990 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature